PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32970826-8	2021	Recent studies have shown clinically significant increases in exposure to CYP2C8 substrates (repaglinide, dasabuvir, desloratidine) and a CYP2B6 substrate (s-sibutramine) following co-administration with clopidogrel, indicating that therapeutic strategies with clopidogrel should avoid these drugs.	dasabuvir	106-115	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
32103133-4	2020	However, being substrates and inhibitors of efflux transporters (TAM inhibits P-gp, DSV inhibits P-gp and BCRP), there is a possibility for a pharmacokinetic (PK) drug-drug interaction.	dasabuvir	84-87	phosphoglycolate phosphatase	Homo sapiens	78-82
32103133-4	2020	However, being substrates and inhibitors of efflux transporters (TAM inhibits P-gp, DSV inhibits P-gp and BCRP), there is a possibility for a pharmacokinetic (PK) drug-drug interaction.	dasabuvir	84-87	phosphoglycolate phosphatase	Homo sapiens	97-101
32103133-4	2020	However, being substrates and inhibitors of efflux transporters (TAM inhibits P-gp, DSV inhibits P-gp and BCRP), there is a possibility for a pharmacokinetic (PK) drug-drug interaction.	dasabuvir	84-87	BCR pseudogene 1	Homo sapiens	106-110
30450781-2	2019	In this phase 3b open-label study, we assessed changes in IFN-stimulated genes (ISGs) in non-cirrhotic treatment-naive or pegIFN/RBV-experienced HCV-GT1a-infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin (PrOD + R) for 12 weeks.	dasabuvir	218-227	interferon alpha 1	Homo sapiens	58-61
29696643-1	2019	Dasabuvir is mainly metabolized by cytochrome P450 (CYP) 2C8 and is predominantly used in a regimen containing ritonavir.	dasabuvir	0-9	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	35-60
28579812-13	2017	Detailed analysis of the costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + dasabuvir+-RBV with an average cost of $24,978 (RBV+) and $25,448 (RBV-) per patient was the most cost-effective.	dasabuvir	114-123	beta-1,4-galactosyltransferase 1	Homo sapiens	35-39
28258380-10	2017	Coadministration of dasabuvir with a strong CYP2C8 inhibitor increased dasabuvir exposures by greater than tenfold, whereas coadministration with strong CYP3A inhibitors increased dasabuvir exposures by less than 50%.	dasabuvir	20-29	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	44-50
28258380-11	2017	Furthermore, coadministration of dasabuvir with a CYP3A inducer decreased dasabuvir exposures by 55-70%.	dasabuvir	33-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-55
28258380-11	2017	Furthermore, coadministration of dasabuvir with a CYP3A inducer decreased dasabuvir exposures by 55-70%.	dasabuvir	74-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-55
28258380-12	2017	Coadministration of dasabuvir with strong CYP2C8 inhibitors or strong CYP3A/CYP2C8 inducers is contraindicated.	dasabuvir	20-29	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	42-48
28411400-1	2017	Dasabuvir, a nonnucleoside NS5B polymerase inhibitor, is a sensitive substrate of cytochrome P450 (CYP) 2C8 with a potential for drug-drug interaction (DDI) with clopidogrel.	dasabuvir	0-9	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	82-107
28444890-1	2017	Dasabuvir, a component of VIEKIRA PAK, is a substrate of CYP2C8 enzymes.	dasabuvir	0-9	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	57-63
28444890-3	2017	Clopidogrel may increase dasabuvir exposures primarily due to CYP2C8 inhibition by clopidogrel-acyl-beta-D-glucuronide.	dasabuvir	25-34	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	62-68
28483778-6	2017	Paritaprevir, ritonavir, and dasabuvir are BCRP inhibitors.	dasabuvir	29-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-47
28483778-9	2017	Strong CYP2C8 inhibitors increased plasma exposure of dasabuvir (a major CYP2C8 substrate), OATP1B1/1B3 inhibitors increased plasma exposure of paritaprevir (an OATP1B1/1B3 substrate), and P-gp or BCRP inhibitors (all compounds are substrates of P-gp and/or BCRP) increased plasma exposure of the 3D regimen.	dasabuvir	54-63	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	7-13
28483778-9	2017	Strong CYP2C8 inhibitors increased plasma exposure of dasabuvir (a major CYP2C8 substrate), OATP1B1/1B3 inhibitors increased plasma exposure of paritaprevir (an OATP1B1/1B3 substrate), and P-gp or BCRP inhibitors (all compounds are substrates of P-gp and/or BCRP) increased plasma exposure of the 3D regimen.	dasabuvir	54-63	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	73-79
30384028-16	2018	CONCLUSION: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for 12 weeks is effective among people with HCV genotype 1 with recent injecting drug use and/or receiving OST.	dasabuvir	52-61	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	195-198
26436610-0	2016	Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.	dasabuvir	111-120	microRNA 122	Homo sapiens	6-13
27179126-9	2016	Dasabuvir was cleared mainly through cytochrome P450-mediated oxidation metabolism to M1.	dasabuvir	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-52
27179126-12	2016	Cytochrome P450 profiling indicated that dasabuvir was mainly metabolized by CYP2C8, followed by CYP3A4.	dasabuvir	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
27179126-12	2016	Cytochrome P450 profiling indicated that dasabuvir was mainly metabolized by CYP2C8, followed by CYP3A4.	dasabuvir	41-50	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	77-83
27179126-12	2016	Cytochrome P450 profiling indicated that dasabuvir was mainly metabolized by CYP2C8, followed by CYP3A4.	dasabuvir	41-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
26488159-9	2015	Contraindicated associations/potential interactions were expected between cART and respectively sofosbuvir (0.2%/0%), sofosbuvir/ledipasvir (0.2%/67.6%), daclatasvir (0%/49.4%), ombitasvir/boosted paritaprevir (with or without dasabuvir) (34.4%/52.2%) and simeprevir (78.8%/0%).	dasabuvir	227-236	CART prepropeptide	Homo sapiens	74-78
26721703-3	2016	CYP2C8 substrate drugs include amodiaquine, cerivastatin, dasabuvir, enzalutamide, imatinib, loperamide, montelukast, paclitaxel, pioglitazone, repaglinide, and rosiglitazone, and the number is increasing.	dasabuvir	58-67	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
35524830-0	2022	hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +- Ribavirin Therapy Efficacy in Hepatitis C Infection.	dasabuvir	75-84	microRNA 17	Homo sapiens	0-10
35524830-3	2022	The expression profiles of miR-223-3p, miR-17-5p, miR-24-3p, and TLR2 - 196 to - 174 del/ins polymorphisms from the blood/serum of 34 hepatitis C virus (HCV)-infected patients pre- and post-ombitavir/paritaprevir/ritonavir + dasabuvir treatment were determined by RT-qPCR.	dasabuvir	225-234	toll like receptor 2	Homo sapiens	65-69
34718654-3	2022	Dasabuvir is an anti-hepatitis C drug reported to inhibit several UGT isoforms.	dasabuvir	0-9	beta-1,3-glucuronyltransferase 2	Homo sapiens	66-69
34718654-9	2022	Dasabuvir produced strong partial inhibition effect of UGT1A1 and UGT1A9 and relatively complete inhibition of UGT1A6.	dasabuvir	0-9	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	55-61
34718654-9	2022	Dasabuvir produced strong partial inhibition effect of UGT1A1 and UGT1A9 and relatively complete inhibition of UGT1A6.	dasabuvir	0-9	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	66-72
34718654-9	2022	Dasabuvir produced strong partial inhibition effect of UGT1A1 and UGT1A9 and relatively complete inhibition of UGT1A6.	dasabuvir	0-9	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	111-117
34718654-10	2022	CONCLUSIONS: Consistent with previous reports, dasabuvir inhibits the activity of 3 UGT isoforms associated with APAP metabolism.	dasabuvir	47-56	beta-1,3-glucuronyltransferase 2	Homo sapiens	84-87